Merus Labs and Norgine Enter into a Definitive Arrangement Agreement

Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash
 
TORONTO and AMSTERDAM, May 11, 2017  - Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement Agreement") under which Norgine will acquire all of the issued and outstanding common shares of Merus for $1.65 per share in cash including the assumption of all debt obligations, for a total enterprise value of approximately $342 million (the "Arrangement"). The transaction will be financed through a combination of available cash and new credit facilities that Norgine has secured prior to executing the Arrangement. The transaction price of $1.65 per share represents a premium of 63.4% to the closing price of $1.01 on the TSX on May 10, 2017 and a premium of 55.1% over the 30-day volume weighted average price of $1.06 on the TSX.
Read more: Merus Labs International ( MSL / MSLI )

Valeant Pharma earns $628-million (U.S.) in Q1 2017

Mr. Joseph Papa reports -  VALEANT ANNOUNCES FIRST QUARTER 2017 RESULTS AND RAISES FULL YEAR ADJUSTED EBITDA GUIDANCE RANGE
 
Valeant Pharmaceuticals International Inc. has released its first quarter 2017 financial results (all amounts are in U.S. dollars).
"Our first quarter performance demonstrates that we are delivering on our commitments. We met our internal expectations, and we are continuing to make progress on our key initiatives, focus on the turnaround of our core businesses and improve internal operating efficiencies," said Joseph C. Papa, chairman and chief executive officer, Valeant. "Our divestiture efforts and cash flow generation have led to a $3.6 billion reduction in total debt to date, since the end of the first quarter of 2016, and our successful debt refinancing provides us with a more comfortable maturity profile."
Read more: Valeant Pharmaceuticals International ( VRX )

PetMed Express, Inc. D/B/A 1-800-PETMEDS Announces Its Financial Results for Fiscal 2017 and Its Quarterly Dividend Raised to $0.20 Per Share

Fourth Quarter Net Income Increased 38% 
Fourth Quarter New Order Sales Increased 17%
Fourth Quarter Net Sales Increased 14%
 
DELRAY BEACH, Fla., May 08, 2017 -- PetMed Express, Inc. (NASDAQ:PETS) today announced its financial results for the fiscal year ended March 31, 2017.  Net sales for the quarter ended March 31, 2017 were $63.0 million, compared to $55.4 million for the quarter ended March 31, 2016, an increase of 14%.  For the fiscal year ended March 31, 2017 net sales were $249.2 million, compared to $234.7 million for the fiscal year ended March 31, 2016, an increase of 6.2%.  The increase in sales for the quarter ended March 31, 2017 can be attributed to a 17% increase in new order sales, and a 13% increase in reorder sales. 
Read more: PetMed Express Inc ( PETS )

SteadyMed Raises $30 Million in Private Placement

SteadyMed prepares to file New Drug Application (NDA) for Trevyent® in Q2 2017
 
Financing provides capital for Trevyent commercial launch preparation
 
SAN RAMON, Calif., April 21, 2017 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered into a definitive agreement to sell its ordinary shares and warrants to purchase its ordinary shares for aggregate gross proceeds of approximately $30 million in a private placement. The financing was led by Adage Capital Management, OrbiMed, Deerfield Management and Kingdon Capital Management.
Read more: SteadyMed Ltd ( STDY )

Theratechnologies to buy ibalizumab commercial rights

Mr. Luc Tanguay reports
 
THERATECHNOLOGIES ACQUIRES COMMERCIAL RIGHTS TO IBALIZUMAB IN THE EUROPEAN UNION AND FOUR ADDITIONAL TERRITORIES
 
Theratechnologies Inc. has reached an agreement with TaiMed Biologics Inc. for the acquisition of the commercial rights to ibalizumab in the European Union, Israel, Norway, Russia and Switzerland.
 
Ibalizumab is an investigational humanized monoclonal antibody currently being developed for the potential treatment of multidrug resistant (MDR) HIV-1 infection. Theratechnologies first acquired the commercial rights to ibalizumab in the United States and Canada in March 2016. The existing agreement between both companies has been amended to include the additional territories and related new obligations.
Read more: Theratechnologies Inc ( TH )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker